boston scientif corp engag develop
manufactur market medic devic
use broad rang intervent medic
specialti compani product technolog
use diagnos treat wide rang medic
vascular urolog women health chronic pain
condit compani headquart natick
reason report
estim chang analysi sales/earn
reiter invest rate price target
share importantli requisit element remain in-plac
enabl compani sustain top-tier organ revenu earn
growth potenti enhanc growth
margin profil long-term accordingli share trade
slight premium slower grow peer averag despit potenti
rel out-perform versu consensu estim continu
recommend share rate price target
reiter price reiter per share price
target assum ev/ebitda multipl
non-gaap earn multipl
chang estim increas revenu
cash earn estim billion per share
billion per share respect likewis
increas former revenu estim billion
billion former cash earn estim per
share per share earn estim revis
summar tabl left
guidanc summari establish revenu guidanc
rang billion billion pre-cal consensu
billion impli revenu growth report
basi also establish cash earn guidanc rang
pre-cal consensu assum
adjust gross margin adjust oper margin
addit expect compani adjust
effect tax rate oper period
establish revenu guidanc rang billion
billion pre-cal consensu billion impli growth
report basi establish cash ep guidanc
rang pre-cal consensu
assum adjust gross margin rang
adjust oper margin adjust effect tax rate
valuat summari share current valu ev/
revenu ebitda cash
earn versu slower grow industri peer trade averag like
multipl respect figur
import disclosur analyst certif page report access current disclosur stephen
inc cover compani client may refer
free oper period gener approxim million adjust free cash
flow versu million prior year period due compani pay million btg relat debt
gener billion adjust free cash flow slightli compani target billion
result time capit expenditur increas work capit requir
sentinel updat conjunct earn releas announc sentinel cerebr embol
protect devic avail hospit addit compani estim sentinel
penetr domest tavr procedur lastli begin enrol compani protect
tcr random control trial oper period
divers new product pipelin lend confid sustain peer growth intervent
cardiolog segment lotu edg expect launch japan limit market releas come month
follow reimburs approv next gener accur launch eu addit
synergi megatron remain track launch peripher intervent stand benefit
integr btg addit launch ranger dcb endoscopi exalt-d contribut
segment oper period follow devic limit market releas urology/pelv
benefit intern expans spaceoar rezum domest eu launch tria
ureter stent cardiac rhythm manag segment compani remain track launch lux-dx
icm mid expect limit revenu contribut turn electrophysiolog compani directsens
cathet remain track launch later follow success launch europ japan lastli
continu anticip global launch compani db next gener visual platform
becton dickinson compani
note data reflect stephen estim other consensu ep reflect adjust cash ep
stephen inc estim
consolid statement incom
million except per share data
good sold
research develop
sale market administr
fiscal period
fiscal period
fiscal period
incom prior tax
weight averag share issu outstand
compani report stephen inc estim
analyst primarili respons prepar content report certifi view express report
accur reflect analyst person view subject compani secur ii part analyst compens
directli indirectli relat specif recommend view express analyst report
